<DOC>
	<DOCNO>NCT00388505</DOCNO>
	<brief_summary>This study compare safety tobramycin solution inhalation tobramycin dry powder formulation , use simple inhaler</brief_summary>
	<brief_title>Safety Tobramycin Inhalation Powder ( TIP ) v Tobramycin Solution Inhalation Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Confirmed diagnosis cystic fibrosis Male female patient least 6 year age time screen . Forced expiratory volume one second ( FEV1 ) screen must least 25 % less equal 75 % normal predict value age , sex , height base Knudson criterion . Pseudomonas aeruginosa , type bacteria , must present sputum/deepthroat cough swab culture ( bronchoalveolar lavage [ BAL ] ) within 6 month prior screen sputum/ deepthroat cough swab culture screen visit . Able comply protocol requirement . Clinically stable opinion investigator . Use effective mean contraception female childbearing potential . Provide write informed consent , Health Authority Portability Accountability Act ( HIPAA ) authorization ( applicable ) , assent ( appropriate ) prior performance studyrelated procedure . History sputum culture deepthroat cough swab ( BAL ) culture yield Burkholderia cepacia ( B cepacia ) , type bacteria , within 2 year prior screen and/or sputum culture yield B cepacia screening . Coughing 60 cc blood respiratory tract time within 30 day prior study drug administration . Known local systemic hypersensitivity aminoglycosides inhale antibiotic . Females pregnant ( positive pregnancy test ) , lactate , plan become pregnant study . History hearing loss chronic ring ear deem clinically significant investigator . Use systemic inhale antipseudomonal antibiotic within 28 day prior study drug administration . Use loop diuretic within 7 day prior study drug administration . Use investigational treatment within 28 day prior study drug administration . Initiation treatment chronic macrolide therapy , dornase alpha treatment inhaled corticosteroid within 28 day prior study drug administration ( patient may take therapy time enrollment , must initiate treatment 28 day prior study drug administration ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>tobramycin</keyword>
</DOC>